TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33448753

Group type: EXPERIMENTAL
Intervention: Therapist-driven cognitive rehabilitation (TCR)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation (CCR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TCR
Number of subjects: 32
Study: 34188114

Group type: EXPERIMENTAL
Intervention: Stroke lesions in the right putamen and internal capsules of both hemispheres
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Injuries of the cortico-spinal tracts
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Striato-capsular lesions
Number of subjects: 329
Study: 32615659

Group type: EXPERIMENTAL
Intervention: Krocina™
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 36451437

Group type: EXPERIMENTAL
Intervention: Educational music intervention (twice-weekly group sessions for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34370401

Group type: EXPERIMENTAL
Intervention: High-intensity intervention group (assessments plus weekly sessions)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Low-intensity control group (home-based assessments)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: High-intensity intervention group
Number of subjects: 199
Study: 32115450

Group type: EXPERIMENTAL
Intervention: Fortified group 2 (FG2) with 76 mg/100 g bovine lactoferrin (bLF)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fortified group 1 (FG1) with 38 mg/100 g bovine lactoferrin (bLF)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (FG0) with no bovine lactoferrin (bLF)
Number of subjects: 108
Study: 35397279

Group type: EXPERIMENTAL
Intervention: Interpersonal emotion regulation intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition (no manipulation of emotion regulation strategies)
Number of subjects: 19
Study: 32507649

Group type: EXPERIMENTAL
Intervention: Platelet index score (PIS) incorporating high platelet count (PLT ≥350), high mean platelet volume (MPV ≥8.8), and low platelet distribution width (PDW <12.1)
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Nomograms based on the platelet index score (PIS) and clinicopathological features
Number of subjects: 1198
Study: 35918295

Group type: EXPERIMENTAL
Intervention: Endoscopic polymer foam (EPF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Endobronchial valve control group (EBV-CTRL)
Number of subjects: 14
Study: 32019822

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation screening device (AFSD)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: 12-lead ECG
Number of subjects: 1518
Study: 34449490

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Remifentanil (group R)
Number of subjects: 61
Study: 34215981

Group type: EXPERIMENTAL
Intervention: Maternal exposure to bisphenol A (BPA) measured in urinary concentration
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Serum β‐hCG level measured in mIU/ml
Number of subjects: 120
Study: 33221700

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil (860 mg DHA + 120 g EPA/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Corn oil (isocaloric control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil
Number of subjects: 61
Study: 35959802

Group type: EXPERIMENTAL
Intervention: Salmon milt (SM) DNA for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33780888

Group type: EXPERIMENTAL
Intervention: Body Project condition
Number of subjects: 141

Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 141
Study: 32859272

Group type: EXPERIMENTAL
Intervention: Couple-based treatment
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 1332
Study: 35477483

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham electroacupuncture (SEA)
Number of subjects: 60
Study: 34106211

Group type: EXPERIMENTAL
Intervention: Dichoptic training under noise-free conditions
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dichoptic training on all tasks
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dichoptic training
Number of subjects: 116

Group type: COMPARATOR
Intervention: No training group
Number of subjects: 116
Study: 33663491

Group type: EXPERIMENTAL
Intervention: Intervention group (education for GPs about pain management in AOM)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 224
Study: 36175973

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 123
Study: 33494781

Group type: EXPERIMENTAL
Intervention: burst SCS paradigm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 kHz SCS paradigm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.499 kHz SCS paradigm
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo stimulation
Number of subjects: 60
Study: 32234756

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with gemcitabine (Gem)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Observation only (Obs)
Number of subjects: 101
Study: 35868334

Group type: EXPERIMENTAL
Intervention: Liraglutide (one daily subcutaneous injection uptitrated from 0.6-1.8 mg per day over 3 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Colesevelam (three capsules of 625 mg twice daily)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Colesevelam
Number of subjects: 52
Study: 34754004

Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions (education and follow-up plan)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 131
Study: 32682483

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study: 34798039

Group type: EXPERIMENTAL
Intervention: Etrolizumab (n=384)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo (n=95)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Etrolizumab to etrolizumab (n=117)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Etrolizumab to placebo (n=115)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Etrolizumab (induction)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo (induction)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Etrolizumab to etrolizumab (maintenance)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Etrolizumab to placebo (maintenance)
Number of subjects: 609
Study: 34158575

Group type: EXPERIMENTAL
Intervention: Obese children (n=150)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Non-obese children (n=531)
Number of subjects: 681
Study: 36274797

Group type: EXPERIMENTAL
Intervention: Modified Peres' height formula (height of patient (cm)/10-2)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Distance between puncture site and right third intercostal space (PS‐RTICS) - 1
Number of subjects: 400
Study: 33882206

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 468

Group type: COMPARATOR
Intervention: Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
Number of subjects: 468
Study: 33955109

Group type: EXPERIMENTAL
Intervention: HER2−/HR+ in EBC
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: HER2+ in EBC
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: Triple negative in EBC
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: HER2−/HR+ in MBC
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: HER2+ in MBC
Number of subjects: 6977

Group type: EXPERIMENTAL
Intervention: Triple negative in MBC
Number of subjects: 6977
Study: 35227152

Group type: EXPERIMENTAL
Intervention: No stoma
Number of subjects: 54

Group type: COMPARATOR
Intervention: Stoma
Number of subjects: 54
Study: 33227549

Group type: EXPERIMENTAL
Intervention: Smoking cessation (lower smoking burden score)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Smoking burden score (SBS)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Baseline cigarettes per day (CPD)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 726
Study: 34887446

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-chemotherapy
Number of subjects: 0
Study: 32145372

Group type: EXPERIMENTAL
Intervention: Go/No-go training for highly palatable (HP) food
Number of subjects: 561

Group type: COMPARATOR
Intervention: General inhibitory control (control group)
Number of subjects: 561
Study: 37592484

Group type: EXPERIMENTAL
Intervention: Hydrogel perirectal spacer (SpaceOAR® system)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Fiducial markers alone (control group)
Number of subjects: 222
Study: 33904667

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 32588671

Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser (control group)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Sequential therapy with 755-nm long-pulsed alexandrite laser and 595-nm pulsed dye laser (experimental group)
Number of subjects: 194
Study: 33160115

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 33810258

Group type: EXPERIMENTAL
Intervention: Infliximab + vitamin-D
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo-infliximab + vitamin-D
Number of subjects: 40
Study: 35415743

Group type: EXPERIMENTAL
Intervention: Motor Skills intervention (instructional lessons, peer modeling videos, behavioral scaffolding, structured activities)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Motor Skills intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Free Play (control group)
Number of subjects: 72
Study: 34265088

Group type: EXPERIMENTAL
Intervention: CBD 10 mg/kg/day (CBD10)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: CBD 20 mg/kg/day (CBD20)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: CBD (combined CBD10 and CBD20)
Number of subjects: 318
Study: 32523337

Group type: EXPERIMENTAL
Intervention: Hospital-outreach pulmonary rehabilitation program
Number of subjects: 208

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 208
Study: 33740048

Group type: EXPERIMENTAL
Intervention: Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet (LFD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional dietary advice (TDA)
Number of subjects: 100
Study: 32396038

Group type: EXPERIMENTAL
Intervention: Pilates program (36 weeks, twice weekly)
Number of subjects: 12
Study: 35399836

Group type: EXPERIMENTAL
Intervention: Family nursing service intervention
Number of subjects: 150
Study: 34172505

Group type: EXPERIMENTAL
Intervention: Routine care plus phone-based weekly pill refilling and daily medication reminders
Number of subjects: 306

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 306
Study: 32428227

Group type: EXPERIMENTAL
Intervention: Continuous theta-burst transcranial magnetic stimulation to the dorsal inferior parietal lobule (dIPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline dIPL-M1 and aIPL-M1 cortico-cortical interactions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortical silent period measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dIPL-PMv resting state functional connectivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline PMv-M1 interactions
Number of subjects: 0
Study: 34655304

Group type: EXPERIMENTAL
Intervention: Penile skin graft (PSG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Buccal mucosa graft (BMG)
Number of subjects: 100
Study: 34918634

Group type: EXPERIMENTAL
Intervention: Core muscle strengthening exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: General stretching exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intergroup analysis
Number of subjects: 40
Study: 34551581

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) - 40 ml 0.125% SB plus 20 ml of LB
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard bupivacaine (SB) - 60 ml of 0.25% SB
Number of subjects: 78
Study: 34949392

Group type: EXPERIMENTAL
Intervention: Interventional closure of the iASD
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative therapy (CT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MITHRAS cohort (iASD present)
Number of subjects: 80
Study: 35850363

Group type: EXPERIMENTAL
Intervention: NBTXR3 plus external-beam radiotherapy (EBRT) (Arm A)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Radiotherapy alone (Arm B)
Number of subjects: 179
Study: 34165501

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT) 50 Gy
Number of subjects: 394

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT)
Number of subjects: 394
Study: 35246723

Group type: EXPERIMENTAL
Intervention: CardioMEMS™ HF-System implantation
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 554
Study: 36208718

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait List Control (WL)
Number of subjects: 240
Study: 33782190

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 69
Study: 32379347

Group type: EXPERIMENTAL
Intervention: Random selection of single colonies from agar plates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-genomic sequencing technologies
Number of subjects: 0
Study: 33471484

Group type: EXPERIMENTAL
Intervention: Proactive specialized inflammatory bowel diseases (IBD) emergency department consultation and multidisciplinary IBD team (IBD‐MDT) intervention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Computed tomography during hospital admission
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Surgical interventions during hospital admission
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 45
Study: 35063116

Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg orally twice per day for 12 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 45
Study: 33733338

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Savolitinib 300 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Savolitinib (both doses)
Number of subjects: 0
Study: 32521287

Group type: EXPERIMENTAL
Intervention: Persuasive e‐cigarette prevention video ads from The Real Cost campaign
Number of subjects: 543

Group type: COMPARATOR
Intervention: Information‐only e‐cigarette harms control videos
Number of subjects: 543
Study: 36448618

Group type: EXPERIMENTAL
Intervention: Wireless full-HD Augmented Reality Head-Mounted Display (AR-HMD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: TV Monitors (TVM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both HMD and TVM
Number of subjects: 38
Study: 32920957

Group type: EXPERIMENTAL
Intervention: Fortasyn Connect (125 mL once-a-day drink)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo control drink (isocaloric, same tasting)
Number of subjects: 311
Study: 32689756

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ringer's sodium lactate (Control)
Number of subjects: 48
Study: 34473645

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg, Trulicity)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 34
Study: 32947496

Group type: EXPERIMENTAL
Intervention: Lactic acid (LA) at doses of 30, 60, or 120 mg/mL
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (iohexol, 1.5 mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lactic acid (LA) at doses of 60, 120 mg/mL
Number of subjects: 15
Study: 35041662

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (increased physical activity, weight loss target 7% through meal replacements and medication Orlistat)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Standard lifestyle intervention (increased physical activity alone without targeted weight loss)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 379

Group type: COMPARATOR
Intervention: Standard lifestyle intervention
Number of subjects: 379
Study: 34925513

Group type: EXPERIMENTAL
Intervention: Chest-to-back skin-to-skin contact (CB SSC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chest-to-chest skin-to-skin contact (CC SSC)
Number of subjects: 46
Study: 34447234

Group type: EXPERIMENTAL
Intervention: 30% of goal caloric requirements (group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 60% of goal caloric requirements (group B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 100% of goal caloric requirements (group C)
Number of subjects: 54
Study: 32278640

Group type: EXPERIMENTAL
Intervention: Health education intervention in the interventional school
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control school (no specific intervention mentioned)
Number of subjects: 398
Study: 35365036

Group type: EXPERIMENTAL
Intervention: EPPM-STM
Number of subjects: 101
Study: 33736994

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for chronic endometritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not including chronic endometritis in initial baseline study
Number of subjects: 0
Study: 34950454

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 36463027

Group type: EXPERIMENTAL
Intervention: High-voltage PRF (60 V)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-voltage PRF (45 V)
Number of subjects: 41
Study: 33401239

Group type: EXPERIMENTAL
Intervention: Optimum Power Load Training (OPT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 20
Study: 33186312

Group type: EXPERIMENTAL
Intervention: Nonremoval of the blocker at the end of the pilot tube
Number of subjects: 408

Group type: COMPARATOR
Intervention: Removal of the blocker and actively deflating the cuff before SLMA insertion
Number of subjects: 408
Study: 33220710

Group type: EXPERIMENTAL
Intervention: Routine physiotherapy with neuromobilization (NM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine physiotherapy (care group)
Number of subjects: 80
Study: 35089607

Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with pomalidomide and dexamethasone (D‐Pd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone (Pd)
Number of subjects: 0
Study: 33330958

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) 2 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) after sham re-treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham/IVT-AFL
Number of subjects: 54
Study: 36207063

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at 1000-3000 mg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Fosphenytoin (FPHT) at 22.5 mg/kg
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Fosphenytoin (FPHT)
Number of subjects: 176
Study: 33404895

Group type: EXPERIMENTAL
Intervention: CHF1535 (beclometasone dipropionate 50 μg and formoterol fumarate 6 μg via pMDI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CHF1535 (beclometasone dipropionate 100 μg and formoterol fumarate 12 μg via pMDI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CHF1535 (beclometasone dipropionate 200 μg and formoterol fumarate 24 μg via pMDI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Free combination of beclometasone dipropionate and formoterol fumarate
Number of subjects: 56
Study: 32865652

Group type: EXPERIMENTAL
Intervention: vanucizumab (experimental, E)
Number of subjects: 189

Group type: COMPARATOR
Intervention: bevacizumab (control, C)
Number of subjects: 189
Study: 35568380

Group type: EXPERIMENTAL
Intervention: Preventure intervention (two 90-minute sessions, one week apart)
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Usual health education only (control)
Number of subjects: 1636
Study: 34736575

Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2) 1 mg/day plus vaginal progesterone (P4) 45 mg/day for 10 days each month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36282369

Group type: EXPERIMENTAL
Intervention: Radiography group (n = 81) with assistance of right ventriculography
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-radiography group (n = 27)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Radiography group (n = 81)
Number of subjects: 108
Study: 33745439

Group type: EXPERIMENTAL
Intervention: MTX test (20 mg, 2 × 10 mg capsules)
Number of subjects: 52

Group type: COMPARATOR
Intervention: MTX reference (20 mg, 2 × 10 mg capsules)
Number of subjects: 52
Study: 32276315

Group type: EXPERIMENTAL
Intervention: 0.7 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g/day (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.35 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Number of subjects: 0